Voluntary nationwide recall: Clonazepam (Endo – July)

Sep. 2024Pharmacy Updates

Endo USA Inc. has recalled one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. Clonazepam is used to treat panic disorder and certain seizures.

This product is being recalled because the cartons of some packs show the product strength as 0.125 mg, not 0.25 mg, due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25 mg.

Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.

As of July 16, there had been no reports of adverse events related to this recall.

To learn more about this recall:

  • Call Inmar Inc. at 1-877-890-0765. Help is available Monday through Friday from 9 a.m. to 5 p.m. ET.
  • Visit the FDA website.

Recent Announcements

CME/CEU Webinar: Bright Beginnings: The Role of Medical and Dental Providers in Early Oral Health

Please join us for a live, CME-accredited and CEU-accredited webinar on Monday, Aug. 24 from noon to 1 p.m., that will educate providers on the importance of early childhood oral health.
Jun. 2026Education/Webinars

Provider OnLine Multi-Factor Authentication Enhancements coming soon

Microsoft changes and security enhancements will soon require Provider OnLine users to complete multi-factor authentication (MFA) each time they log in to access the portal. MFA is a security feature that adds an extra layer of protection by requiring more than just a password. This MFA requirement is expected to take effect on June 25, 2026.
Jun. 2026Important Notices

Voluntary nationwide recall: Dexcom G7 sensors (June 2026)

Dexcom, Inc. is recalling two lots of Dexcom G7 sensors. Dexcom G7 sensors are used to monitor blood glucose levels as part of the Dexcom Glucose Monitoring system.
Jun. 2026Pharmacy Updates